Curis appoints Dr. John A. Hohneker to Board of Directors

CURIS INC

Dr. Hohneker elected as Class II director on Dec 2, 2021, term until 2022 annual meeting.
Receives standard non-employee director compensation: one-time option for 25,000 shares vesting over 4 years.
Brings 30 years of drug development experience; former President/CEO of Anokion and President of R&D at FORMA Therapeutics.
Expected to help advance CA-4948 (IRAK4 inhibitor) toward potential approval and commercialization.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John A. Hohneker, M.D.

Director

CRIS · CURIS INC

Effective: 2021-12-02
Filed: December 6, 2021, 6:59 PM ET

On December 2, 2021, the Board of Directors (“Board”) of Curis, Inc. (the “Company”) elected John A. Hohneker, M.D., to serve as a class II director until the 2022 Annual Meeting of Stockholders and thereafter until his successor is duly elected and qualified.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John A. Hohneker, M.D. was elected as Director at CURIS INC.

Action: elected
Role: Director

Exact text from the filing

On December 2, 2021, the Board of Directors (“Board”) of Curis, Inc. (the “Company”) elected John A. Hohneker, M.D., to serve as a class II director until the 2022 Annual Meeting of Stockholders and thereafter until his successor is duly elected and qualified.

View on SEC.gov

CURIS INC filing history →

Source: SEC EDGAR

accession 0001193125-21-348468

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.